Regardless of XPC expression, all NSCLC cell lines required treatment with higher concentrations of CSE to develop similar levels of DNA damage by alkaline Comet assay compared to benign bronchial epithelial cells (Beas-2B) (Figure 3). The gene discussed is XPC; the disease is non-small cell lung carcinoma.